These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 30242791)

  • 41. IL-1 Contributes to the Anti-Cancer Efficacy of Ingenol Mebutate.
    Le TT; Skak K; Schroder K; Schroder WA; Boyle GM; Pierce CJ; Suhrbier A
    PLoS One; 2016; 11(4):e0153975. PubMed ID: 27100888
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy and safety of ingenol mebutate 0.015% gel 3 weeks after cryosurgery of actinic keratosis: 11-week results.
    Berman B; Goldenberg G; Hanke CW; Tyring SK; Werschler WP; Knudsen KM; Goncalves J; Larsson T; Skov T; Swanson N
    J Drugs Dermatol; 2014 Feb; 13(2):154-60. PubMed ID: 24509965
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Randomized, double-blind, double-dummy, vehicle-controlled study of ingenol mebutate gel 0.025% and 0.05% for actinic keratosis.
    Anderson L; Schmieder GJ; Werschler WP; Tschen EH; Ling MR; Stough DB; Katsamas J
    J Am Acad Dermatol; 2009 Jun; 60(6):934-43. PubMed ID: 19467365
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Sequential use of photodynamic therapy and imiquimod 5% cream for the treatment of actinic cheilitis: a 12-month follow-up study.
    Sotiriou E; Lallas A; Goussi C; Apalla Z; Trigoni A; Chovarda E; Ioannides D
    Br J Dermatol; 2011 Oct; 165(4):888-92. PubMed ID: 21916880
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Aphthous ulcers associated with imiquimod and the treatment of actinic cheilitis.
    Chakrabarty AK; Mraz S; Geisse JK; Anderson NJ
    J Am Acad Dermatol; 2005 Feb; 52(2 Suppl 1):35-7. PubMed ID: 15692510
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Treatment of Imiquimod Resistant Epidermodysplasia Verruciformis With Ingenol Mebutate.
    Kim C; Hashemi P; Caglia M; Shulman K
    J Drugs Dermatol; 2016 Mar; 15(3):350-2. PubMed ID: 26954321
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Multiple Treatment-Resistant Actinic Keratoses Secondary to Hydroxycarbamide.
    Bhoyrul B; Brent G; Abdul-Kadir I; Mikeljevic J
    Skinmed; 2017; 15(6):489-491. PubMed ID: 29282196
    [No Abstract]   [Full Text] [Related]  

  • 48. [Photodynamic therapy for actinic cheilitis].
    Castaño E; Comunión A; Arias D; Miñano R; Romero A; Borbujo J
    Actas Dermosifiliogr; 2009 Dec; 100(10):895-8. PubMed ID: 20038368
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Photodynamic therapy: treatment of choice for actinic cheilitis?
    Rossi R; Assad GB; Buggiani G; Lotti T
    Dermatol Ther; 2008; 21(5):412-5. PubMed ID: 18844720
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Ingenol mebutate gel for actinic keratosis.
    Lebwohl M; Swanson N; Anderson LL; Melgaard A; Xu Z; Berman B
    N Engl J Med; 2012 Mar; 366(11):1010-9. PubMed ID: 22417254
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pharmacoeconomic evaluations in the treatment of actinic keratoses.
    Tolley K; Argenziano G; Calzavara-Pinton PG; Larsson T; Ryttig L
    Int J Immunopathol Pharmacol; 2017 Jun; 30(2):178-181. PubMed ID: 28580871
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cosmetic Effects of Ingenol Mebutate Gel in the Treatment of Field-Cancerized Photodamaged Skin.
    Braun SA; Gerber PA
    Dermatol Surg; 2015 Nov; 41(11):1328-9. PubMed ID: 26448312
    [No Abstract]   [Full Text] [Related]  

  • 53. Mediators of Inflammation in Topical Therapy of Skin Cancers.
    Voiculescu VM; Lisievici CV; Lupu M; Vajaitu C; Draghici CC; Popa AV; Solomon I; Sebe TI; Constantin MM; Caruntu C
    Mediators Inflamm; 2019; 2019():8369690. PubMed ID: 30766448
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparison of the efficacy and tolerability of 3% diclofenac sodium gel and 5% imiquimod cream in the treatment of actinic keratosis.
    Kose O; Koc E; Erbil AH; Caliskan E; Kurumlu Z
    J Dermatolog Treat; 2008; 19(3):159-63. PubMed ID: 18569272
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Safety and tolerability of ingenol mebutate in the treatment of actinic keratosis.
    Berman B
    Expert Opin Drug Saf; 2015; 14(12):1969-78. PubMed ID: 26524598
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pharmacokinetic and pharmacodynamic evaluation of ingenol mebutate for the treatment of actinic keratosis.
    Stockfleth E; Bastian M
    Expert Opin Drug Metab Toxicol; 2018 Sep; 14(9):911-918. PubMed ID: 30074409
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pharmacokinetics of ingenol mebutate gel under maximum use conditions in large treatment areas.
    Bucko AD; Jarratt M; Stough DB; Kyhl L; Villumsen J; Hall A
    J Dermatolog Treat; 2018 Feb; 29(1):74-79. PubMed ID: 28524709
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Field cancerization: from molecular basis to selective field-directed management of actinic keratosis.
    Philipp-Dormston WG
    Curr Probl Dermatol; 2015; 46():115-21. PubMed ID: 25561215
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Use of ingenol mebutate gel for actinic keratosis in patients in a community dermatology practice.
    Bettencourt MS
    J Drugs Dermatol; 2014 Mar; 13(3):269-73. PubMed ID: 24595570
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Reduced degree of irritation during a second cycle of ingenol mebutate gel 0.015% for the treatment of actinic keratosis.
    Jim On SC; Haddican M; Yaroshinsky A; Singer G; Lebwohl M
    Cutis; 2015 Jan; 95(1):47-51. PubMed ID: 25671445
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.